A metabolic comparison of <scp>GIPR</scp> agonism versus <scp>GIPR</scp> antagonism in male mice
Our data highlights the distinct metabolic effects of GIPR agonism and antagonism, offering insights for their future application in personalised metabolic disease treatments. Further human studies are needed to understand the long-term metabolic impacts of these therapies.
Authors
- Tricia Tan (ORCID: https://orcid.org/0000-0001-5873-3432)
- Kevin G. Murphy (ORCID: https://orcid.org/0000-0002-3417-0310)
- Cecilia Dunsterville
- Carissa Wong (ORCID: https://orcid.org/0000-0003-3431-8896)
- Huy Tran (ORCID: https://orcid.org/0000-0002-9057-060X)
- Ben Jones (ORCID: https://orcid.org/0000-0003-0461-2584)
- Iona Davies
- Yichang Sun
- Olivier Cahn
- Yi Xiao (ORCID: https://orcid.org/0000-0002-3817-3471)
- S.R. Bloom
- Alexandra Turland
Institutions
- Imperial College London (GB)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1111/dom.70300
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Wellcome Trust
- National Institute for Health and Care Research
- Diabetes UK
- Imperial College London
- Directorate for Biological Sciences
- Medical Research Council